1. Home
  2. MRNA

MRNA

Moderna Inc.

Logo Moderna Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Founded: 2010 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 41.0B IPO Year: 2018
Target Price: $132.00 AVG Volume (30 days): 4.0M
Analyst Decision: Hold Number of Analysts: 17
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -12.33 EPS Growth: N/A
52 Week Low/High: $62.55 - $163.24 Next Earning Date: 05-02-2024
Revenue: $6,848,000,000 Revenue Growth: -64.45%
Revenue Growth (this year): -37.56% Revenue Growth (next year): 11.65%

Share on Social Networks: